Benjamin Graham fit · Defensive deep-value investing
Is Xeris Biopharma Holdings, Inc. Common Stock (XERS) a Benjamin Graham Stock?
Meets only 3/7 Graham criteria — likely overpriced or unstable.
11/100
FNot a fit
3/7 criteria passed
Benjamin Graham's Criteria, Applied to XERS
P/E ≤ 15
key—
P/B ≤ 1.5
key0.0x
Current ratio ≥ 2
1.9x
Debt / Equity ≤ 1
0.0x
How XERS Scores on Other Strategies
Live Financial Snapshot
Market cap
$1.36B
P/E (TTM)
92.7x
ROIC (TTM)
12.84%
Gross margin
81.59%
Other Benjamin Graham fit reports
Frequently Asked Questions
What is XERS's Benjamin Graham fit score?
XERS scores 11/100 on our Benjamin Graham fit engine — grade F. Meets only 3/7 Graham criteria — likely overpriced or unstable.
Does Benjamin Graham actually own XERS?
Our score is computed from financial fundamentals against Benjamin Graham's published criteria. We don't claim that Benjamin Graham personally owns or recommends XERS.
How often is this score updated?
XERS's Benjamin Graham fit score is recomputed daily from the latest TTM financials.
Educational tool, not investment advice. Scores are computed from publicly-available financial data against published investing-strategy criteria. We do not claim that Benjamin Graham personally owns or recommends XERS.